1. Home
  2. GSL vs PGEN Comparison

GSL vs PGEN Comparison

Compare GSL & PGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GSL

Global Ship Lease Inc New

HOLD

Current Price

$38.34

Market Cap

1.4B

ML Signal

HOLD

Logo Precigen Inc.

PGEN

Precigen Inc.

HOLD

Current Price

$4.16

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GSL
PGEN
Founded
2007
1998
Country
Greece
United States
Employees
7
N/A
Industry
Marine Transportation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.4B
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
GSL
PGEN
Price
$38.34
$4.16
Analyst Decision
Strong Buy
Buy
Analyst Count
2
5
Target Price
$43.50
$8.33
AVG Volume (30 Days)
232.1K
5.2M
Earning Date
05-18-2026
05-13-2026
Dividend Yield
6.64%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$230,981,000.00
Revenue This Year
N/A
$1,115.92
Revenue Next Year
N/A
$81.04
P/E Ratio
$3.49
N/A
Revenue Growth
N/A
N/A
52 Week Low
$21.05
$1.23
52 Week High
$41.40
$5.47

Technical Indicators

Market Signals
Indicator
GSL
PGEN
Relative Strength Index (RSI) 50.54 56.73
Support Level $36.82 $3.97
Resistance Level $38.52 $4.43
Average True Range (ATR) 0.93 0.23
MACD -0.05 0.00
Stochastic Oscillator 41.28 60.53

Price Performance

Historical Comparison
GSL
PGEN

About GSL Global Ship Lease Inc New

Global Ship Lease Inc is a containership owner, leasing ships to container shipping companies under industry-standard, fixed-rate time charters. Its fleet comprises mid-size Post-Panamax, Cypress, and smaller containerships, which tend to serve the faster-growing non-Mainlane and intra-regional trades, collectively representing the majority of the containerized trade volume globally. The company generates revenue from chartering its vessels to liner companies.

About PGEN Precigen Inc.

Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.

Share on Social Networks: